New cancer drug combo enters first human tests
NCT ID NCT06031441
First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 5 times
Summary
This early-stage trial is testing an experimental drug called RO7566802, alone or with the immunotherapy atezolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of activity. About 250 participants will take part in this first-in-human study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RO7566802 (an experimental drug) and atezolizumab (Tecentriq, an immunotherapy)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is a very early (Phase 1) trial, so the main goal is safety, not effectiveness. The drug may not work or could have serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Addenbrooke's Hospital
Cambridge, CB2 0QQ, United Kingdom
-
British Columbia Cancer Agency - 600 10th Ave W
Vancouver, British Columbia, V5Z 4E6, Canada
-
Churchill Hospital
Oxford, OX3 7LJ, United Kingdom
-
Icahn School of Medicine at Mount Sinai (ISMMS)
New York, New York, 10029, United States
-
Leicester Royal Infirmary
Leicester, LE1 5WW, United Kingdom
-
Magee-Woman's Hospital
Harrisburg, Pennsylvania, 17109, United States
-
National Cancer Centre
Singapore, 168583, Singapore
-
National University Hospital
Singapore, 119074, Singapore
-
Peter Maccallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 1Z5, Canada
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute
London, W1G 6AD, United Kingdom
-
St Bartholomew's Hospital
London, EC1A 7BE, United Kingdom
-
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, 2010, Australia
-
The Ohio State University
Columbus, Ohio, 43221-3502, United States
-
The Royal Marsden hospital
Sutton, SM2 5PT, United Kingdom
-
University of Alabama at Birmingham (UAB)
Birmingham, Alabama, 35233, United States
-
Yale Cancer Center
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?